Harrow Closes TYRVAYA Buy, Adds $30M Revenue Target for 2027

Harrow (Nasdaq: HROW) announced on 5 October 2026 that it closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris, paying $30 million in cash at closing with up to $70 million more in contingent milestone payments tied to net sales, for potential total consideration of up to $100 million. The company said the closing payment was funded with cash on hand. TYRVAYA is the first and only FDA-approved nasal spray for dry eye disease, and Harrow now holds worldwide rights to it everywhere except Japan.

Context — Why Does This Dry Eye Deal Matter Now?

The transaction was first announced in August 2026, and the terms disclosed at closing match what Harrow set out then: $30 million upfront, $70 million in sales-linked milestones, $100 million ceiling. Harrow said it expects TYRVAYA to contribute more than $30 million in revenue in 2027, which frames the upfront cash outlay as roughly one year of the acquired product's own expected sales.

That ratio is the core of the deal thesis. Harrow is not paying a multiple of today's TYRVAYA revenue; it is paying for a brand it believes it can grow through an existing commercial machine. The company said TYRVAYA arrives with meaningful physician awareness, an established prescription base, and years of real-world clinical experience.

The catalyst chain is straightforward. Harrow already sells VEVYE (cyclosporine ophthalmic solution) 0.1%, its flagship prescription dry eye therapy, through an Ocular Surface commercial organization. Adding TYRVAYA gives that same field force a second branded product to detail to the same ophthalmologists and optometrists. Harrow said both products already use PhilRx as their primary specialty pharmacy, so the patient-support and distribution rails are shared rather than duplicated.

The macro backdrop for specialty pharma is not the driver here. This is an asset-level integration story: what changed is ownership, not the underlying dry eye market. Harrow is a Nasdaq-listed ophthalmic disease management company with a portfolio spanning dry eye, wet age-related macular degeneration, cataracts, refractive errors, and glaucoma.

Data — What Do the Numbers Show?

The headline figures are the $30 million cash paid at closing, the up-to-$70 million milestone pool, the up-to-$100 million total consideration, and the more-than-$30 million 2027 revenue expectation for TYRVAYA. Harrow said the upfront payment came from cash on hand, so no new financing was disclosed alongside the close.

The deal also brings people, not just a product. Harrow said it expects approximately 40 experienced personnel from Viatris, with established knowledge of TYRVAYA and the dry eye market, to join and augment its existing Ocular Surface commercial team, with onboarding expected during the fourth quarter of 2026. That is a material addition to a specialty sales force, and it arrives with product-specific relationships already in place.

Item	Detail
Cash at closing	$30 million
Contingent milestones	Up to $70 million
Total consideration ceiling	Up to $100 million
2027 revenue expectation	More than $30 million
Personnel expected to join	Approximately 40
Territory acquired	Worldwide, excluding Japan

The geographic carve-out is a second revenue line. Viatris retained the right to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Harrow did not disclose the royalty rate. TYRVAYA is approved in the U.S., China, and Taiwan, with marketing applications pending in additional markets, per the company.

Analysis — What It Means for Harrow and the Dry Eye Sector

The second-order effect runs through Harrow's commercial cost base. Two brands sharing one specialty pharmacy, one patient-support function, and one field organization means incremental TYRVAYA revenue should carry a lower marginal cost than a standalone launch would. Harrow framed this as leveraging shared commercial, market access, patient-support, and operational infrastructure across both brands.

The clinical positioning is the differentiator. TYRVAYA is a cholinergic agonist administered through the nose, and the company said it is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. VEVYE is applied directly to the ocular surface. For contact lens wearers and patients who struggle with drops, that nasal route is a genuinely separate option rather than a reformulation.

The counter-argument is integration risk and milestone dilution. Harrow is absorbing roughly 40 people from a larger global healthcare company into a single therapeutic franchise, and it has committed to up to $70 million in future payments if TYRVAYA's net sales hit undisclosed thresholds. Harrow did not disclose the milestone triggers, so the market cannot model when that cash leaves the balance sheet. If the sales curve disappoints, the headline $100 million ceiling understates the real cost of the deal relative to what was bought.

Positioning-wise, this is a franchise-consolidation trade. Investors long HROW are effectively underwriting the company's ability to cross-sell between two dry eye brands using one sales force. Viatris exits the commercial burden outside Japan while keeping royalty exposure, a structure that shifts execution risk to Harrow.

Outlook — What to Watch Next

The first checkpoint is the fourth-quarter 2026 onboarding of the approximately 40 Viatris personnel. Harrow said commercial integration begins in the fourth quarter, and the speed of that transition determines how quickly the expanded field force can detail both brands.

The second is whether TYRVAYA revenue tracks toward the more-than-$30 million 2027 figure the company set out. That number is a company expectation, not a reported result, and it is the yardstick investors will use to judge whether the $30 million upfront was well spent.

The third is the pending marketing applications in additional markets beyond the U.S., China, and Taiwan. Harrow did not name those jurisdictions or give approval timelines, so the timing of any incremental geographic revenue is unknown. Japan royalties add a smaller, separate stream that depends on Viatris' own commercialization there. No specific price levels or moving averages for HROW were disclosed in the report.

Frequently Asked Questions

What does the Harrow TYRVAYA acquisition mean for retail investors?

It gives Harrow a second branded dry eye product sold through the same commercial organization as VEVYE, which the company said creates cost-sharing across pharmacy, patient support, and field sales. The financial exposure is the $30 million already paid plus up to $70 million in contingent milestones tied to TYRVAYA net sales. The company's own 2027 expectation is more than $30 million in TYRVAYA revenue.

What happens next for Harrow after the TYRVAYA close?

Harrow said commercial integration begins in the fourth quarter of 2026, with approximately 40 Viatris personnel expected to onboard and support both VEYVE and TYRVAYA. Prescriptions can be routed through electronic medical records to PhilRx or sent to any retail pharmacy. TYRVAYA is stocked in the wholesale channel, including McKesson, Cardinal, and Cencora, and the company said orders generally ship to retail pharmacies within 24 hours.

Why did Harrow structure the TYRVAYA deal with milestone payments?

The company did not disclose the sales thresholds that trigger the up-to-$70 million in contingent payments. Structurally, the split means Harrow pays the full $100 million only if TYRVAYA's net sales reach levels the two parties negotiated. That shifts part of the valuation risk onto Viatris, which also retained Japanese commercialization rights and will pay Harrow royalties on net sales in that market.

Bottom Line

Harrow has bought a differentiated, already-prescribed dry eye brand for $30 million upfront and now has to prove the more-than-$30 million 2027 revenue target.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.